Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2026Cancer Research

Abstract LB423: Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous recombination deficient (HRD) pancreatic cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMarc HilmiWMWilson McKerrowJSJoshua D. Schoenfeld

Discussion

Loading...

Member takes

Overview

Demonstrates enhanced T cell responses in HRD pancreatic cancer, indicating strong immunogenic potential despite resistance mechanisms.

Key Points

  • Investigate the characteristics and functionality of tumor-infiltrating T cell clonotypes in exceptional responders to dual therapy.
  • Analyzed 53 primary and metastatic samples using spatial transcriptomics.
  • Identified rare TCR clonotypes in exceptional responders through a customized gene panel.
  • Conducted functional T cell assays to explore immune responses against predicted neoepitopes.
  • TIE+ clonotypes were present at diagnosis and persisted for over 3 years post-treatment.
  • These clonotypes comprised 1.49% of the CD8 T cell population in exceptional responders.
  • Proximity to tumor cells and enhanced cytotoxicity were observed prior to disease progression.

Cite This Study

Hilmi et al. (2026) studied this question.

synapsesocial.com/papers/69e4739a010ef96374d8f6d8https://doi.org/10.1158/1538-7445.am2026-lb423
View Full Paper
Ask AI
Bookmark
Share